ArticleBMC cancer2025
CA 15 - 3 may be a promising biomarker for differentiating distant organ metastasis in breast cancer at initial diagnosis.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImaging techniques for breast cancer identify distant organ metastasis, but can be time-consuming and costly. This study compares clinicopathological and laboratory data between metastatic and nonmetastatic breast cancer patients at initial diagnosis and evaluates CA 15 - 3's predictive value for distinguishing distant metastases.
methodsThis retrospective study examined 232 untreated breast cancer patients diagnosed between January 2021 and January 2022. They were divided into distant organ metastatic (Group I) and nonmetastatic (Group II) at the initial diagnosis. We analyzed laboratory data, including CA 15 - 3 and CEA levels, and used Receiver Operating Characteristic (ROC) curves to find optimal cut-off values for predicting distant organ metastasis.
resultsForty-nine patients (21.1%) had distant organ metastases at initial diagnosis. Significant differences were found between groups in tumor diameter, neutrophil and lymphocyte counts, T-stage, N-stage, CA 15 - 3, CEA, albumin, alkaline phosphatase, neutrophil-to-lymphocyte ratio, and the systemic immune inflammation index (SII) (all p < 0.05). CA 15 - 3 demonstrated excellent discriminatory ability (AUC = 0.950; 95% CI: 0.924-0.975; p < 0.001). A CA 15 - 3 cutoff value of 25.8 U/mL had 100% sensitivity, 82.5% specificity, 60.5% positive predictive value, and 100% negative predictive value. No patient with a CA 15 - 3 level below 25.8 U/mL presented with distant organ metastasis.
conclusionsCA 15 - 3 demonstrated promising performance in ruling out distant metastases in newly diagnosed breast cancer patients. Further prospective studies are needed to confirm whether using CA 15 - 3 may reduce the time loss and costs associated with routine imaging for distant organ metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.